Company intelligence / Profile preview

Lexeo Therapeutics

New York City, New York, United Stateslexeotx.com ↗

Ownership: Public · LXEO
Development stage: Phase 1

Overview

Positive interim Phase 1/2 data for LX2006 in Friedreich's ataxia cardiomyopathy showing improvement in left ventricular mass index (LVMI) and frataxin expression, supporting advancement to registrational study. Also has ongoing Phase 1/2 trial for LX1001 in APOE4-associated Alzheimer's disease with completed enrollment.

Therapeutic areas: CardiovascularNeurology
Modalities: AAV-mediated gene therapy
Industry: Biotech

Drug pipeline

14 assets

LX1001

13 more assets in the full pipeline.

Request access →

Partnerships

Weill Cornell MedicineUniversity of California San Diego

Financials

Market cap: $342.4M
Total revenue: $0
Enterprise value: $137.5M

Beyond the preview

Go deeper on Lexeo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lexeo Therapeutics.

Explore the full profile